| 1. |
鄭彩虹, 郗光霞, 高林琳, 等. 甲狀腺危象死亡相關危險因素分析. 中國醫師雜志, 2019, 21(7): 1085-1087.
|
| 2. |
M?ller MH, Adamsen S, Thomsen RW, et al. Preoperative prognostic factors for mortality in peptic ulcer perforation: a systematic review. Scand J Gastroenterol, 2010, 45(7-8): 785-805.
|
| 3. |
黃衛東, 姚美芬. 甲亢危象的診治. 中華危重癥醫學雜志: 電子版, 2010, 3(1): 1-5.
|
| 4. |
王玉付. 脾破裂合并甲狀腺危象的1例體會. 內蒙古中醫藥, 2014, 33(3): 129.
|
| 5. |
李金榮. 外科急腹癥合并甲狀腺機能亢進圍手術期的處理 (附19例分析). 吉林醫學, 2012, 33(7): 1356-1357.
|
| 6. |
Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol, 2009, 104(3): 728-738.
|
| 7. |
國家風濕病數據中心, 中國系統性紅斑狼瘡研究協作組. 非甾體消炎藥相關消化道潰瘍與潰瘍并發癥的預防與治療規范建議. 中華內科雜志, 2017, 56(1): 81-85.
|
| 8. |
M?ller MH, Adamsen S, W?jdemann M, et al. Perforated peptic ulcer: how to improve outcome? Scand J Gastroenterol, 2009, 44(1): 15-22.
|
| 9. |
Nuhu A, Kassama Y. Experience with acute perforated duodenal ulcer in a West African population. Niger J Med, 2008, 17(4): 403-406.
|
| 10. |
S?reide K, Thorsen K, Harrison EM, et al. Perforated peptic ulcer. Lancet, 2015, 386(10000): 1288-1298.
|
| 11. |
Boey J, Choi SK, Poon A, et al. Risk stratification in perforated duodenal ulcers. A prospective validation of predictive factors. Ann Surg, 1987, 205(1): 22-26.
|
| 12. |
Buck DL, Vester-Andersen M, M?ller MH, et al. Surgical delay is a critical determinant of survival in perforated peptic ulcer. Br J Surg, 2013, 100(8): 1045-1049.
|
| 13. |
Ogiso S, Inamoto S, Hata H, et al. Successful treatment of gastric perforation with thyrotoxic crisis. Am J Emerg Med, 2008, 26(9): 1065. e3-e4.
|
| 14. |
Natsuda S, Nakashima Y, Horie I, et al. Thyroid storm precipitated by duodenal ulcer perforation. Case Rep Endocrinol, 2015, 2015: 750390.
|
| 15. |
Williams MJ, Blair DW. Gastric secretion in hyperthyroidism. Br Med J, 1964, 1(5388): 940-944.
|
| 16. |
邵偉, 鞏傳勇. 胃十二指腸潰瘍穿孔合并甲狀腺功能亢進圍手術期處理17例分析. 中國實用外科雜志, 2010, 30(2): 125-126.
|
| 17. |
Zweig SB, Schlosser JR, Thomas SA, et al. Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and critical illness: case report and review of literature. Endocr Pract, 2006, 12(1): 43-47.
|
| 18. |
Abubakar H, Singh V, Arora A, et al. Propranolol-induced circulatory collapse in a patient with thyroid crisis and underlying thyrocardiac disease: a word of caution. J Investig Med High Impact Case Rep, 2017, 5(4): 2324709617747903.
|
| 19. |
Godo S, Kawazoe Y, Ozaki H, et al. Switching therapy from intravenous Landiolol to transdermal bisoprolol in a patient with thyroid storm complicated by decompensated heart failure and gastrointestinal dysfunction. Intern Med, 2017, 56(19): 2603-2609.
|
| 20. |
Yamashita Y, Iguchi M, Nakatani R, et al. Thyroid storm with heart failure treated with a short-acting beta-adrenoreceptor blocker, Landiolol hydrochloride. Intern Med, 2015, 54(13): 1633-1637.
|
| 21. |
黃政坤, 蘇海豐. 甲亢危象合并急性胃穿孔手術麻醉一例. 臨床麻醉學雜志, 2004, 20(7): 396.
|
| 22. |
Wyble AJ, Moore SC, Yates SG. Weathering the storm: a case of thyroid storm refractory to conventional treatment benefiting from therapeutic plasma exchange. J Clin Apher, 2018, 33(6): 678-681.
|